(DHR) Danaher - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2358511028
DHR: Medical, Industrial, Commercial, Biotechnology, Diagnostic, Equipment
Danaher Corporation is a global leader in the development, manufacture, and marketing of innovative products and services across various industries. With a strong focus on technology and scientific advancement, Danahers diversified portfolio spans multiple high-impact sectors, making it a standout player in both innovation and operational efficiency.
The Biotechnology segment at Danaher is pivotal, offering cutting-edge solutions that accelerate the development and production of therapeutics. Their range includes single-use hardware, cell culture media, and filtration technologies, all of which are critical in advancing bioprocessing and manufacturing processes.
In the Life Sciences sector, Danaher provides essential tools such as mass spectrometers and flow cytometry systems, which are vital for genomics and proteomics research. Their portfolio includes well-known brands that deliver high-quality products and services, catering to both research and industrial applications.
The Diagnostics segment focuses on enhancing patient care through advanced diagnostic systems and clinical instruments. Their solutions are integral to healthcare settings, providing timely and accurate diagnoses that improve clinical decision-making.
Danahers strategic collaboration with Stanford Universitys Department of Bioengineering underscores their commitment to innovation, particularly in cancer drug development. This partnership highlights their dedication to advancing medical science and improving patient outcomes.
Founded in 1969 and renamed in 1984, Danaher has established a legacy of excellence and innovation. Their financial health, with a market cap exceeding $150 billion, reflects their strong operational and strategic management. Investors are drawn to their high margins, driven by the Danaher Business System, which emphasizes lean manufacturing and continuous improvement.
Danahers disciplined acquisition strategy has been key to their success, integrating companies that align with their core competencies and driving long-term growth. This approach, combined with their financial strength, positions Danaher as a resilient and attractive investment opportunity.
Additional Sources for DHR Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DHR Stock Overview
Market Cap in USD | 148,350m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1979-01-05 |
DHR Stock Ratings
Growth 5y | 25.3% |
Fundamental | -7.80% |
Dividend | 58.3% |
Rel. Strength Industry | -17.6 |
Analysts | 4.46/5 |
Fair Price Momentum | 175.86 USD |
Fair Price DCF | 93.43 USD |
DHR Dividends
Dividend Yield 12m | 0.47% |
Yield on Cost 5y | 0.79% |
Annual Growth 5y | 11.10% |
Payout Consistency | 91.4% |
DHR Growth Ratios
Growth Correlation 3m | -44.7% |
Growth Correlation 12m | -38.8% |
Growth Correlation 5y | 49.6% |
CAGR 5y | 9.04% |
CAGR/Max DD 5y | 0.25 |
Sharpe Ratio 12m | -0.82 |
Alpha | -29.42 |
Beta | 0.56 |
Volatility | 35.25% |
Current Volume | 6209.8k |
Average Volume 20d | 5682.5k |
What is the price of DHR stocks?
As of February 23, 2025, the stock is trading at USD 210.23 with a total of 6,209,808 shares traded.
Over the past week, the price has changed by +1.90%, over one month by -13.88%, over three months by -10.45% and over the past year by -15.76%.
As of February 23, 2025, the stock is trading at USD 210.23 with a total of 6,209,808 shares traded.
Over the past week, the price has changed by +1.90%, over one month by -13.88%, over three months by -10.45% and over the past year by -15.76%.
Is Danaher a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Danaher is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DHR as of February 2025 is 175.86. This means that DHR is currently overvalued and has a potential downside of -16.35%.
Neither. Based on ValueRay Fundamental Analyses, Danaher is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DHR as of February 2025 is 175.86. This means that DHR is currently overvalued and has a potential downside of -16.35%.
Is DHR a buy, sell or hold?
Danaher has received a consensus analysts rating of 4.46. Therefor, it is recommend to buy DHR.
Danaher has received a consensus analysts rating of 4.46. Therefor, it is recommend to buy DHR.
- Strong Buy: 18
- Buy: 5
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecast for DHR stock price target?
According to ValueRays Forecast Model, DHR Danaher will be worth about 202 in February 2026. The stock is currently trading at 210.23. This means that the stock has a potential downside of -3.9%.
According to ValueRays Forecast Model, DHR Danaher will be worth about 202 in February 2026. The stock is currently trading at 210.23. This means that the stock has a potential downside of -3.9%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 268.3 | 27.6% |
Analysts Target Price | 284.4 | 35.3% |
ValueRay Target Price | 202 | -3.9% |